Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
← catalyst calendarNCT07093580 · readout in 280 d
Sponsored by Shionogi (industry) · 4507.T — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
98estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-29 | actual | When the study began enrolling |
| Primary completion | 2027-05-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-26 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: S-892216-LAI
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
measured Day 1 through Day 364
Part 2: Number of Participants With TEAEs
measured Day 1 through Day 448
Permalink · 4507.T's whole pipeline · Catalyst calendar · Every registered study · What changed